Mirum Pharmaceuticals, Inc. MIRM
NASDAQ · United States · Health Technology
$84.59-0.89 (-1.04%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
Mirum Pharmaceuticals (MIRM) stock is in focus after the company reported that brelovitug met the primary endpoint in the Phase 3 AZURE-1 trial for chronic hepatitis delta virus, supported by 48-week Phase 2b viral suppression data. Recent headlines around brelovitug and the FDA approval of Atebrioz have arrived after a softer patch for Mirum Pharmaceuticals, with the share price down 9.75% over 30 days and 24.87% over 90 days. Even though year to date the share price return is 12.67% and the...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.